ArticleNucleic acids research2026
Prime editing-mediated microhomology enables efficient replacement of large DNA.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Donor-complementary prime editing enables precise kilobase and library-compatible DNA insertions.Nature biotechnology · 2026Article
- Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing.Nature biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Precise and efficient replacement of large genomic DNA segments without inducing double-strand breaks (DSBs) remains a central challenge in genome engineering. Traditional homologous recombination relies on DSBs and long homologous arms, yet it remains inefficient, while recombinase or integrase systems suffer from residual sequences at integration sites. Prime editing (PE), limited by the processivity of reverse transcriptase, struggles to integrate large fragments (>100 bp). To address this challenge, we introduce Prime Editing-Microhomology-Enabled Replacement (PREMIER), a DSB-free platform by installing single-stranded microhomology arms at donor and genomic junctions via PE. In cell lines, PREMIER achieved a mean efficiency of 63.4% (median 65.2%) in diverse target sites, with peak efficiencies reaching 85.9%, exceeding homology-directed repair by 10-20-fold and reducing off-target integrations by over 100-fold compared to nonhomologous end joining. It bypasses the need for long homology arms, simplifies donor preparation, achieves targeted replacement of sequences up to 10.3 kb. In vivo, PREMIER integrates a 6.2-kb oncogene cassette into the mouse liver. Additionally, PREMIER replaces murine Trp53 with human TP53 CDS, generating functional humanized mice. Altogether, PREMIER provides a precise, high-efficiency, and DSB-free strategy for large-scale genome rewriting, offering a powerful tool for complex modeling and therapeutic genome editing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.